Patented technology
Patented GASMAS for all medical application
The innovative technology behind Neola® is based on GASMAS (Gas in Scattering Media Absorption Spectroscopy) method – an innovative non-invasive laser spectroscopy method for measuring gases in body cavities that has been patented by Neola Medical. GASMAS was originally developed by researchers at Division of Atomic Physics at Lund University and originally proven in industrial applications such as food, pharmaceutical, and beverage quality control.
The technology has been further refined by Neola Medical, holding all rights and patents for the medical application of GASMAS. This patented technology aims to bring a new dimension of safety and precision to neonatal intensive care, while potentially reducing the need for harmful X-ray imaging and invasive blood sampling.
Applying GASMAS in Neola®
Neola® uses small, lightweight probes with soft adhesive, designed for the delicate skin of preterm born babies. One probe emits low-intensity near-infrared light through the chest cavity, while another detects the light after it has passed through tissue. The near-infrared light is harmless, causes no significant heating, and is safe for the baby.
A small portion of the light passes through the air-filled cavities of the lungs, where it is absorbed by water vapor and oxygen gas molecules. Advanced algorithms then process this signal to register changes in lung volume and oxygen gas concentration.
NEOLA®
Neonatal Lung Analyzer
Neola® is a stand-alone device placed next to the incubator (a unit that helps infants maintain body temperature and facilitates observation) to monitor the baby. It consists of a main unit with a modern touch screen and accompanying disposable probes that are attached to the baby’s body to perform the measurements. The touch screen continuously displays the values for relative lung volume and oxygen gas concentration in the right and left lung, which are also stored for later analysis.
Monitoring both lungs
Two probes are placed on opposite sides of the chest to continuously monitor each lung independently.
Non-invasive and safe
The probes are entirely non-invasive and do not cause harmful heating of the baby’s delicate skin.
Easily placed and repositioned
The probes can easily be removed and repositioned during routine care, minimizing discomfort and unnecessary stress for the baby.
Single use probe sets
The probes are non-sterile, changed daily and intended for one single patient use only.
Neonatal Lung Monitoring
The innovative technology behind Neola® has the potential to advance how neonatal intensive care units monitor lung function, moving from intermittent and invasive checks to safe, continuous, real-time monitoring.
Impact beyond the NICU
While Neola® is developed for preterm born babies, the technology could be adapted for older children and adults in intensive care settings, addressing an unmet need in respiratory monitoring across all ages.
Platform for future innovation
With strong patent protection and clinically validated potential, Neola Medical’s technology positions the company as a leader in advanced, non-invasive respiratory monitoring for neonatal intensive care.
Explore more of Neola Medical as an Investment
3. Strong Market Potential
The pediatric medical device segment remains underdeveloped and is experiencing strong growth. Neola® has the potential to establish a new standard of care in a global market with recurring revenue opportunities through single-use disposables.